Immunovant's Q1 Loss Wider Than Expected, Pipeline in Progress Zacks Equity Research Aug 6, 2026 IMVT posts a wider quarterly loss as R&D spending rises, but its cash runway supports IMVT-1402 through a planned Graves' disease commercial launch.